Aclaris Therapeutics (ACRS) EBT (2017 - 2025)
Historic EBT for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to -$15.3 million.
- Aclaris Therapeutics' EBT fell 8077.83% to -$15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$145.2 million, marking a year-over-year decrease of 27948.52%. This contributed to the annual value of -$132.1 million for FY2024, which is 4864.15% down from last year.
- Per Aclaris Therapeutics' latest filing, its EBT stood at -$15.3 million for Q3 2025, which was down 8077.83% from -$16.4 million recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' EBT ranged from a high of -$1.9 million in Q4 2023 and a low of -$97.6 million during Q4 2024
- In the last 5 years, Aclaris Therapeutics' EBT had a median value of -$20.3 million in 2021 and averaged -$23.9 million.
- Per our database at Business Quant, Aclaris Therapeutics' EBT skyrocketed by 9361.05% in 2023 and then tumbled by 515145.32% in 2024.
- Quarter analysis of 5 years shows Aclaris Therapeutics' EBT stood at -$22.9 million in 2021, then fell by 27.02% to -$29.1 million in 2022, then skyrocketed by 93.61% to -$1.9 million in 2023, then tumbled by 5151.45% to -$97.6 million in 2024, then surged by 84.29% to -$15.3 million in 2025.
- Its EBT was -$15.3 million in Q3 2025, compared to -$16.4 million in Q2 2025 and -$15.9 million in Q1 2025.